Array Biopharma Inc., of Boulder, Colo., reported data from the safety lead-in of the phase III BEACON CRC study evaluating binimetinib, a MEK inhibitor, encorafenib, a BRAF inhibitor, and Erbitux (cetuximab, Eli Lilly and Co.), an anti-EGFR antibody, in patients with BRAF-mutant colorectal cancer (CRC) whose disease has progressed after one or two prior regimens in the metastatic setting.